JP2009500427A5 - - Google Patents

Download PDF

Info

Publication number
JP2009500427A5
JP2009500427A5 JP2008520417A JP2008520417A JP2009500427A5 JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5 JP 2008520417 A JP2008520417 A JP 2008520417A JP 2008520417 A JP2008520417 A JP 2008520417A JP 2009500427 A5 JP2009500427 A5 JP 2009500427A5
Authority
JP
Japan
Prior art keywords
group
disease
treating
medical condition
melanocortin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008520417A
Other languages
English (en)
Japanese (ja)
Other versions
JP4734411B2 (ja
JP2009500427A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/026586 external-priority patent/WO2007008704A2/en
Publication of JP2009500427A publication Critical patent/JP2009500427A/ja
Publication of JP2009500427A5 publication Critical patent/JP2009500427A5/ja
Application granted granted Critical
Publication of JP4734411B2 publication Critical patent/JP4734411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008520417A 2005-07-08 2006-07-10 メラノコルチン受容体リガンド Active JP4734411B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US60/697,779 2005-07-08
US74885005P 2005-12-09 2005-12-09
US60/748,850 2005-12-09
PCT/US2006/026586 WO2007008704A2 (en) 2005-07-08 2006-07-10 Melanocortin receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009263603A Division JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド

Publications (3)

Publication Number Publication Date
JP2009500427A JP2009500427A (ja) 2009-01-08
JP2009500427A5 true JP2009500427A5 (OSRAM) 2010-01-21
JP4734411B2 JP4734411B2 (ja) 2011-07-27

Family

ID=37637790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008520417A Active JP4734411B2 (ja) 2005-07-08 2006-07-10 メラノコルチン受容体リガンド
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009263603A Active JP5889513B2 (ja) 2005-07-08 2009-11-19 メラノコルチン受容体リガンド
JP2013165312A Pending JP2013253090A (ja) 2005-07-08 2013-08-08 メラノコルチン受容体リガンド
JP2015140154A Active JP5965520B2 (ja) 2005-07-08 2015-07-14 メラノコルチン受容体リガンド

Country Status (20)

Country Link
US (8) US8039435B2 (OSRAM)
EP (6) EP2548568B1 (OSRAM)
JP (4) JP4734411B2 (OSRAM)
KR (2) KR100997177B1 (OSRAM)
CN (5) CN101257916B (OSRAM)
AU (2) AU2006269261B2 (OSRAM)
CA (4) CA2793119C (OSRAM)
DK (4) DK2236151T3 (OSRAM)
ES (4) ES2663916T3 (OSRAM)
FR (1) FR21C1060I2 (OSRAM)
HU (4) HUE055154T2 (OSRAM)
IL (3) IL188545A (OSRAM)
NL (1) NL301150I2 (OSRAM)
NZ (2) NZ565217A (OSRAM)
PL (4) PL2548568T3 (OSRAM)
PT (4) PT3354273T (OSRAM)
RU (2) RU2439079C2 (OSRAM)
SG (1) SG163585A1 (OSRAM)
SI (1) SI3354273T1 (OSRAM)
WO (1) WO2007008704A2 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548568B1 (en) * 2005-07-08 2018-01-10 Ipsen Pharma Melanocortin receptor ligands
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
TW200848424A (en) * 2007-06-15 2008-12-16 Sod Conseils Rech Applic Cyclic peptide melanocortin receptor ligands
CN103316345B (zh) * 2007-11-05 2016-05-18 益普生制药股份有限公司 黑皮质素治疗胰岛素敏感的应用
BRPI0912141A2 (pt) 2008-05-27 2016-07-26 Genzyme Corp análogos de peptídeo do hormônio alfa-melanócito estimulante
EP2300036B1 (en) 2008-06-09 2017-04-05 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
JP2013501053A (ja) * 2009-08-05 2013-01-10 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 脂質異常症を治療するためのメラノコルチンの使用
US8541545B2 (en) * 2009-08-31 2013-09-24 Tensive Controls Inc. Stabilized melanocortin ligands
RU2548753C2 (ru) * 2009-11-16 2015-04-20 Ипсен Фарма С.А.С. Фармацевтические композиции лигандов рецепторов меланокортинов
US20120226018A1 (en) * 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
KR102038677B1 (ko) * 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
ES2732077T3 (es) 2011-12-29 2019-11-20 Rhythm Pharmaceuticals Inc Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
EP2968475A2 (en) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
CN118240012A (zh) * 2013-03-15 2024-06-25 节奏制药公司 肽组合物
EP2970389B1 (en) 2013-03-15 2020-08-19 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
CN106232623A (zh) 2014-04-22 2016-12-14 Txp制药股份有限公司 具有支链氨基酸探针的肽类似物
ES2985734T3 (es) 2015-09-30 2024-11-07 Rhythm Pharmaceuticals Inc Método de tratamiento de trastornos asociados a la vía del receptor de la melanocortina-4
US10653743B2 (en) * 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US20190255142A1 (en) * 2016-10-17 2019-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
EP3596107A1 (en) * 2017-03-15 2020-01-22 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US20210221867A1 (en) * 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2019222851A1 (en) * 2018-05-23 2019-11-28 Provincial Health Services Authority Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
TW202228760A (zh) * 2020-09-24 2022-08-01 美商律森製藥股份有限公司 治療黑素皮質素-4受體路徑相關病症之方法
WO2022251650A1 (en) * 2021-05-27 2022-12-01 The Regents Of The University Of Michigan Mc3r agonist peptides
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2025123059A1 (en) * 2023-12-07 2025-06-12 Endevica Bio, Inc. Non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6127381A (en) * 1998-04-28 2000-10-03 Basu; Amaresh Isoquinoline compound melanocortin receptor ligands and methods of using same
MXPA01001100A (es) * 1998-07-27 2002-08-20 Univ Iowa State Res Found Inc Gen del receptor melanocortina-4 y su uso como un marcador genetico para contenido de grasa, ganacia de peso y7o consumo de alimento para animales.
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
CA2368431C (en) * 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2001033954A1 (en) 1999-11-12 2001-05-17 Merck & Co., Inc. Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AP2001002196A0 (en) * 2000-06-28 2002-12-21 Pfizer Prod Inc Melanocortin receptor ligands.
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MXPA03002160A (es) 2000-09-13 2004-05-04 Eleanor Roosevelt Inst Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
CA2437594A1 (en) 2001-03-02 2002-09-12 Graham S. Poindexter Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
EP1441750A4 (en) * 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
ATE350369T1 (de) 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
US20070293423A1 (en) 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
EP1694348A4 (en) 2003-12-10 2009-07-01 Merck & Co Inc INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
WO2006037188A1 (en) 2004-10-08 2006-04-13 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006073772A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
EP2548568B1 (en) * 2005-07-08 2018-01-10 Ipsen Pharma Melanocortin receptor ligands
US8466104B2 (en) 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues

Similar Documents

Publication Publication Date Title
JP2009500427A5 (OSRAM)
JP2010090130A5 (OSRAM)
RU2009148318A (ru) Лиганды меланокортиновых рецепторов, модифицированные гидантоином
RU2008104803A (ru) Лиганды рецепторов меланокортинов
RU2401841C2 (ru) Лиганды рецепторов меланокортинов
TW200902005A (en) Peripheral opioid receptor antagonists and uses thereof
JP2022547937A (ja) 疼痛の予防および／または処置のためのｎｍｎの使用および対応する組成物
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
JP2017507116A (ja) ｐ−置換非対称尿素及びその医薬的使用
JP2009507921A (ja) ピペラジン化合物のグルクロン酸塩
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
TW434015B (en) 4-aminopyrrole (3, 2-d) pyrimidines as neuropeptide Y receptor antagonists
CA2973746C (en) Prevention or treatment of uratic or gouty diseases
US20120238616A1 (en) Methods and compositions for treating sleep-related breathing disorders
CN108686213B (zh) 冷感觉通道激动剂在制备促进机体冷习服能力的药物中的应用
EP2451452B1 (en) Use of benzydamine in the treatment of p40-dependent diseases
CN114539130B (zh) 苯基哌嗪或苯基哌啶类化合物及其应用
CN106632198A (zh) 芳基乙醇胺槲皮素衍生物及其制备方法和用途
RU2412184C2 (ru) Соли производного пиперазина с салициловой и гентизиновой кислотами
BRPI0615670A2 (pt) composição de liberação prolongada, formulação multiparticulada, e, uso de uma composição e do composto
CN106474113A (zh) 一种用于缺血性脑卒中后神经再生的药物组合物及其应用
CN104208507B (zh) 一种防治小儿惊风的穴位外敷膏
TW201517903A (zh) 便秘症之預防或治療藥
WO2022004788A1 (ja) 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤
WO2006082771A1 (ja) １‐アミノシクロプロパンカルボン酸等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤